SARMs

YK-11 (Myostatin Inhibitor) 25mg

YK-11 (Myostatin Inhibitor) 25mg (25 mg) — Backed by Rotterdam's commitment to quality, a unique compound that functions as both a partial SARM and a myostatin inhibitor. By...

70,00

In Stock (100 available)

Rotterdam · YK-11 (Myostatin Inhibitor) 25mg (25 mg) — Backed by Rotterdam’s commitment to quality, a unique compound that functions as both a partial SARM and a myostatin inhibitor. By…

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost
Categories: ,

Description

YK-11 (Myostatin Inhibitor) 25mg by Rotterdam — Backed by Rotterdam’s commitment to quality, a unique compound that functions as both a partial SARM and a myostatin inhibitor. By inhibiting the myostatin protein — the body’s natural limiter of muscle growth — YK-11 theoretically unlocks genetic muscle-building potential beyond what conventional SARMs or steroids can achieve. It also increases follistatin expression, further antagonizing myostatin’s muscle-limiting effects. This formulation is dosed at 25 mg per unit.

Key Benefits

  • Myostatin inhibitor — uncommon mechanism vs other SARMs
  • Strong lean-mass gains in 8 weeks
  • Hepatotoxic — more so than other SARMs
  • HPTA suppression meaningful at 10+ mg/day
  • Not a beginner SARM — bloodwork at week 4
  • Each unit dosed at 25 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: 5–15 mg/day for 8 weeks. Single daily dose. Split 2× for smoother serum if ALT/AST rise. Full PCT required.

How It Works

Steroidal SARM with added myostatin inhibition — mechanism more similar to follistatin agonists than standard SARMs. Potent mass-builder with distinctive “fullness” effect.

Pharmacokinetics

Plasma half-life approximately 12 hours. Twice-daily dosing smooths serum levels.

Potential Side Effects

Hepatotoxic — more than other SARMs. ALT/AST at week 4 mandatory. HPTA suppression. TUDCA support advised. HDL hit.

Cycle & Stacking Guide

8-week cycles, 5–10 mg/day for most users. Full PCT (Nolva 20 mg/day × 4 weeks). Stacks with Ostarine or Ligandrol for enhanced recomp.

Storage & Handling

Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “YK-11 (Myostatin Inhibitor) 25mg”

Your email address will not be published. Required fields are marked *

Yk 11

Physical & Chemical Properties for Research Purposes
Chemical structure of Yk 11 (C25H34O6) for laboratory analysis
2D structural representation · PubChem CID 25229801 ↗
Chemical Identity
# CAS Registry Number 431579-34-9
Σ IUPAC Name methyl (2E)-2-[(5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-3-methoxyprop-2-enoate
F Molecular Formula C25H34O6
M Molecular Weight 430.54 g/mol
SMILES COC=C(C(=O)OC)[C@]1(O)CC[C@@H]2[C@H]3CC[C@@H]4CC(=O)CC[C@]4(C)[C@@H]3CC[C@@]12C
InChIKey KGFUAIPJJCMYOF-UDMDCWFCSA-N
Melting Point 170-174 °C
Solubility Soluble in DMSO, ethanol; insoluble in water
Biological Half-life 6-10 hours (oral)
PubChem CID 25229801 ↗
Pharmacological Profile
Anabolic Rating N/A (myostatin inhibitor)
Androgenic Rating N/A (partial AR agonist)
Aromatization None
Hepatotoxicity Moderate
Detection Time 2-3 weeks
Known trade names: YK-11, YK11

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.